| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | Adecatumumab Basic information |
| Product Name: | Adecatumumab | | Synonyms: | Adecatumumab;Research Grade Adecatumumab (DHD17402);MT 201;Research Grade Adecatumumab;Adecatumumab (anti-EpCAM) | | CAS: | 503605-66-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Adecatumumab Structure]() |
| | Adecatumumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Adecatumumab Usage And Synthesis |
| Uses | Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status[1][2]. | | in vivo | Adecatumumab (300 μg/mouse; i.v. bolus injection; 3 times per week) inhibits tumor growth in B16/EpCAM xenograft tumor model in mice, both of human adecatumumab and mu-adecatumumab[2].
Both human adecatumumab and mu-adecatumumab (300 μg/mouse; i.v. bolus injection; single dose) exhibit a bi-exponential curve progression of serum concentration with an early distribution phase between 0 and 10 h and a terminal elimination phase[2].
| Animal Model: | Female immunocompetent C57BL/6 mice (6-10 weeks old) with B16/EpCAM (i.v.)[2] | | Dosage: | 250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab | | Administration: | 250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab | | Result: | Both of them exhibited anti-tumor activity against B16/EpCAM cells in mice.
Although human adecatumumab inhibited the size of tumor colonies mice, the number of colonies was only slightly reduced after treatment without significant difference.
In contrast, mu-adecatumumab induced a highly significant reduction in the number of lung tumor colonies by >85%, and the few remaining tumor colonies were of very small size. |
| | References | [1] Kurtz JE, et al. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8. DOI:10.1517/14712598.2010.482098
[2] Lutterbuese P, et al. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother. 2007 Apr;56(4):459-68. DOI:10.1007/s00262-006-0218-7 |
| | Adecatumumab Preparation Products And Raw materials |
|